Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin ... Business Wire (press release) Infinity is currently enrolling patients in DYNAMO, a Phase 2 study evaluating the safety and efficacy of IPI-145 in approximately 120 patients with refractory iNHL whose disease is refractory to radioimmunotherapy or to both rituximab and chemotherapy ... |
